PMID- 37662977
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230905
IS  - 1178-6973 (Print)
IS  - 1178-6973 (Electronic)
IS  - 1178-6973 (Linking)
VI  - 16
DP  - 2023
TI  - A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the 
      Advantages Over Conventional Therapies for Eradication of Helicobacter pylori: A 
      Non-Inferiority Clinical Trial.
PG  - 5637-5645
LID - 10.2147/IDR.S417711 [doi]
AB  - PURPOSE: The emergence of resistant strains has greatly reduced the eradication 
      rate of H. pylori (HP) in conventional bismuth-containing quadruple therapy. 
      Meanwhile, the new 7-day dual therapy with vonoprazan (VPZ) and amoxicillin (AMO) 
      failed to achieve the expected therapeutic effect in China. PATIENTS AND METHODS: 
      A total of 256 untreated HP-infected patients are included in this 
      non-inferiority clinical trial. The patients were randomly divided into three 
      groups: 14-day dual therapy group (VPZ 20mg b.i.d + AMO 750mg t.i.d for 14 days, 
      VA14), 14-day modified triple therapy group (VA14 + Jinghua Weikang Capsule 160mg 
      t.i.d, VAC), and conventional bismuth-containing quadruple therapy group for 14 
      days (BCQ). Eradication rates, drug-related adverse events (AEs), patient 
      compliance, and drug costs were compared among the three groups. RESULTS: The 
      eradication rates in the BCQ, VA14, and VAC were 78.67, 77.33%, and 86.49% by 
      intention-to-treat analysis, respectively, and 96.72%, 90.63%, and 92.75% by 
      pre-protocol or modified intention-to-treat analysis, respectively. VA14 therapy 
      indicated a non-inferiority eradication rate and advanced safety and economics to 
      BCQ therapy. JWC further improved the eradication rate and reduced the incidence 
      of AEs. CONCLUSION: A modified 14-day dual therapy with VPZ and AMO provides 
      satisfied efficacy as the first-line treatment for HP infection in China.
CI  - (c) 2023 Li et al.
FAU - Li, Juan
AU  - Li J
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing City, People's Republic of China.
FAU - Lv, Lin
AU  - Lv L
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing City, People's Republic of China.
FAU - Zhu, Yongjun
AU  - Zhu Y
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing City, People's Republic of China.
FAU - Zhou, Zhihang
AU  - Zhou Z
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing City, People's Republic of China.
FAU - He, Song
AU  - He S
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing City, People's Republic of China.
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
DEP - 20230828
PL  - New Zealand
TA  - Infect Drug Resist
JT  - Infection and drug resistance
JID - 101550216
PMC - PMC10473400
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - Jinghua Weikang capsule
OT  - amoxicillin
OT  - vonoprazan
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/09/04 06:41
MHDA- 2023/09/04 06:42
PMCR- 2023/08/28
CRDT- 2023/09/04 04:52
PHST- 2023/04/18 00:00 [received]
PHST- 2023/08/02 00:00 [accepted]
PHST- 2023/09/04 06:42 [medline]
PHST- 2023/09/04 06:41 [pubmed]
PHST- 2023/09/04 04:52 [entrez]
PHST- 2023/08/28 00:00 [pmc-release]
AID - 417711 [pii]
AID - 10.2147/IDR.S417711 [doi]
PST - epublish
SO  - Infect Drug Resist. 2023 Aug 28;16:5637-5645. doi: 10.2147/IDR.S417711. 
      eCollection 2023.